Dannielle Appelhans - 31 Jan 2023 Form 4 Insider Report for Rubius Therapeutics, Inc.

Role
CEO and President
Signature
/s/ Jennifer Kamocsay, attorney-in-fact
Issuer symbol
N/A
Transactions as of
31 Jan 2023
Net transactions value
-$970
Form type
4
Filing time
01 Feb 2023, 20:40:03 UTC
Previous filing
12 Aug 2022
Next filing
27 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RUBY Common Stock Options Exercise +7,500 +111% 14,263 31 Jan 2023 Direct F1
transaction RUBY Common Stock Sale $970 -3,878 -27% $0.2500* 10,385 01 Feb 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RUBY Restricted Stock Units Options Exercise $0 -7,500 -25% $0.000000 22,500 31 Jan 2023 Common Stock 7,500 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person.
F3 The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney